Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report)'s share price rose 1.1% during trading on Thursday . The company traded as high as $1.92 and last traded at $1.88. Approximately 25,278 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 253,080 shares. The stock had previously closed at $1.86.
Aadi Bioscience Trading Up 5.9%
The stock has a 50 day simple moving average of $1.81 and a 200 day simple moving average of $2.21. The firm has a market capitalization of $49.15 million, a PE ratio of -0.87 and a beta of 0.68.
Hedge Funds Weigh In On Aadi Bioscience
Several hedge funds have recently made changes to their positions in the business. QVT Financial LP purchased a new position in shares of Aadi Bioscience during the fourth quarter valued at approximately $7,300,000. Acorn Capital Advisors LLC purchased a new position in shares of Aadi Bioscience during the fourth quarter valued at approximately $3,619,000. Ally Bridge Group NY LLC purchased a new position in shares of Aadi Bioscience during the fourth quarter valued at approximately $2,581,000. Geode Capital Management LLC increased its stake in shares of Aadi Bioscience by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 217,294 shares of the company's stock valued at $686,000 after buying an additional 8,546 shares during the period. Finally, Bridgeway Capital Management LLC increased its stake in shares of Aadi Bioscience by 23.7% during the fourth quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company's stock valued at $364,000 after buying an additional 22,100 shares during the period. 52.08% of the stock is owned by hedge funds and other institutional investors.
About Aadi Bioscience
(
Get Free Report)
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
Featured Articles
Before you consider Aadi Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list.
While Aadi Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
